Moxonidin Heumann (Moxonidine)

Moxonidine selectively activates imidazoline I1 receptors in the brainstem. This activation dampens sympathetic outflow, leading to reduced peripheral vascular resistance and a modest decrease in heart rate, which together lower arterial blood pressure.

The exact dose of Moxonidin Heumann is determined by the prescribing clinician based on the individual’s blood pressure, response to therapy, and any co‑existing medical conditions. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

The safety of moxonidine in pregnancy and lactation has not been fully established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Moxonidine belongs to the imidazoline receptor agonist class, which reduces sympathetic tone centrally. Unlike ACE inhibitors or calcium‑channel blockers, it does not directly affect the renin‑angiotensin system or calcium channels, offering an alternative mechanism that can be useful in patients who need additional blood‑pressure control or who experience side‑effects from other classes.

Moxonidin Heumann tablets should be stored at room temperature, below 25 °C, in the original blister pack or container. Keep the product away from moisture, heat and direct sunlight to maintain stability.

The medication is taken orally, usually once daily with or without food, as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

Serious adverse events, although rare, can include severe hypotension, marked bradycardia, liver enzyme elevations, and allergic reactions such as rash or swelling. Patients should seek immediate medical attention if they experience fainting, rapid heartbeat, severe dizziness, or signs of an allergic response.

Moxonidin Heumann is contraindicated in patients with known hypersensitivity to moxonidine or any excipients in the tablet. Caution is advised for individuals with severe renal or hepatic impairment, and it should be avoided in patients taking other central antihypertensives without close medical supervision.